Innovative CKD management: AstraZeneca’s Zibotentan/Dapagliflozin advances to Phase III

Innovative CKD management: AstraZeneca’s Zibotentan/Dapagliflozin advances to Phase III

Recent findings from the ZENITH-CKD Phase IIb trial, conducted by AstraZeneca, have demonstrated a significant decrease in albuminuria among CKD patients treated with a combination of Zibotentan and Dapagliflozin. The trial has brought to light a notable decrease in the urinary albumin-to-creatinine ratio (UACR) in participants, offering a new avenue for CKD treatment. Significant UACR […]